Xeris Biopharma scores FDA approval for endogenous Cushing's syndrome drug Recorlev ...

Retrieved on: 2021-12-30 22:52:56

Tags for this article:

Click the tags to see associated articles and topics

Xeris Biopharma scores FDA approval for endogenous Cushing's syndrome drug Recorlev .... View article details on hiswai:

Excerpt

Ahead of its New Year's Day decision deadline at the FDA, Xeris Biopharma has snagged an approval for Recorlev, a drug formerly known as ...

Article found on: www.fiercepharma.com